167 related articles for article (PubMed ID: 38077210)
1. Spatial architecture of high-grade glioma reveals tumor heterogeneity within distinct domains.
Moffet JJD; Fatunla OE; Freytag L; Kriel J; Jones JJ; Roberts-Thomson SJ; Pavenko A; Scoville DK; Zhang L; Liang Y; Morokoff AP; Whittle JR; Freytag S; Best SA
Neurooncol Adv; 2023; 5(1):vdad142. PubMed ID: 38077210
[TBL] [Abstract][Full Text] [Related]
2. A map of the spatial distribution and tumour-associated macrophage states in glioblastoma and grade 4 IDH-mutant astrocytoma.
Yin W; Ping YF; Li F; Lv SQ; Zhang XN; Li XG; Guo Y; Liu Q; Li TR; Yang LQ; Yang KD; Liu YQ; Luo CH; Luo T; Wang WY; Mao M; Luo M; He ZC; Cao MF; Chen C; Miao JY; Zeng H; Wang C; Zhou L; Yang Y; Yang X; Wang QH; Feng H; Shi Y; Bian XW
J Pathol; 2022 Oct; 258(2):121-135. PubMed ID: 35723032
[TBL] [Abstract][Full Text] [Related]
3. Spatially resolved transcriptomic profiles reveal unique defining molecular features of infiltrative 5ALA-metabolizing cells associated with glioblastoma recurrence.
Andrieux G; Das T; Griffin M; Straehle J; Paine SML; Beck J; Boerries M; Heiland DH; Smith SJ; Rahman R; Chakraborty S
Genome Med; 2023 Jul; 15(1):48. PubMed ID: 37434262
[TBL] [Abstract][Full Text] [Related]
4. Impact of redox-related genes on tumor microenvironment immune characteristics and prognosis of high-grade gliomas.
Yuan Y; Zuo M; Zhang S; Chen S; Feng W; Wang Z; Chen M; Liu Y
Front Cell Neurosci; 2023; 17():1155982. PubMed ID: 37252189
[TBL] [Abstract][Full Text] [Related]
5. Identification of the immune gene expression signature associated with recurrence of high-grade gliomas.
Roura AJ; Gielniewski B; Pilanc P; Szadkowska P; Maleszewska M; Krol SK; Czepko R; Kaspera W; Wojtas B; Kaminska B
J Mol Med (Berl); 2021 Feb; 99(2):241-255. PubMed ID: 33215304
[TBL] [Abstract][Full Text] [Related]
6. Spatial transcriptomics reveals segregation of tumor cell states in glioblastoma and marked immunosuppression within the perinecrotic niche.
Liu M; Ji Z; Jain V; Smith VL; Hocke E; Patel AP; McLendon RE; Ashley DM; Gregory SG; López GY
Acta Neuropathol Commun; 2024 Apr; 12(1):64. PubMed ID: 38650010
[TBL] [Abstract][Full Text] [Related]
7. Spatial transcriptomics reveals niche-specific enrichment and vulnerabilities of radial glial stem-like cells in malignant gliomas.
Ren Y; Huang Z; Zhou L; Xiao P; Song J; He P; Xie C; Zhou R; Li M; Dong X; Mao Q; You C; Xu J; Liu Y; Lan Z; Zhang T; Gan Q; Yang Y; Chen T; Huang B; Yang X; Xiao A; Ou Y; Su Z; Chen L; Zhang Y; Ju Y; Zhang Y; Wang Y
Nat Commun; 2023 Feb; 14(1):1028. PubMed ID: 36823172
[TBL] [Abstract][Full Text] [Related]
8. Uncovering Spatiotemporal Heterogeneity of High-Grade Gliomas: From Disease Biology to Therapeutic Implications.
Comba A; Faisal SM; Varela ML; Hollon T; Al-Holou WN; Umemura Y; Nunez FJ; Motsch S; Castro MG; Lowenstein PR
Front Oncol; 2021; 11():703764. PubMed ID: 34422657
[TBL] [Abstract][Full Text] [Related]
9. Quantitative Clinical Imaging Methods for Monitoring Intratumoral Evolution.
Kim JY; Gatenby RA
Methods Mol Biol; 2017; 1513():61-81. PubMed ID: 27807831
[TBL] [Abstract][Full Text] [Related]
10. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
Cohen A; Sato M; Aldape K; Mason CC; Alfaro-Munoz K; Heathcock L; South ST; Abegglen LM; Schiffman JD; Colman H
Acta Neuropathol Commun; 2015 Jun; 3():34. PubMed ID: 26091668
[TBL] [Abstract][Full Text] [Related]
11. Integration analysis of single-cell and spatial transcriptomics reveal the cellular heterogeneity landscape in glioblastoma and establish a polygenic risk model.
Liu Y; Wu Z; Feng Y; Gao J; Wang B; Lian C; Diao B
Front Oncol; 2023; 13():1109037. PubMed ID: 37397378
[TBL] [Abstract][Full Text] [Related]
12. Immuno-phenotyping of IDH-mutant grade 3 astrocytoma and IDH-wildtype glioblastoma reveals specific differences in cells of myeloid origin.
Raghavan JV; Ganesh RA; Sonpatki P; Naik D; John AE; Arunachalam P; Shah D; P S H; Lakshmikantha A; Pillai S; Chandrachari KP; Mariswamappa K; Lale S; Shah N; Jhunjhunwala S
Oncoimmunology; 2021; 10(1):1957215. PubMed ID: 34377594
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional Characteristics of
Chang YZ; Li GZ; Pang B; Zhang KN; Zhang XH; Wang YZ; Jiang ZL; Chai RC
Front Cell Dev Biol; 2020; 8():580464. PubMed ID: 33195221
[No Abstract] [Full Text] [Related]
14. Dysfunctional dendritic cells limit antigen-specific T cell response in glioma.
Friedrich M; Hahn M; Michel J; Sankowski R; Kilian M; Kehl N; Günter M; Bunse T; Pusch S; von Deimling A; Wick W; Autenrieth SE; Prinz M; Platten M; Bunse L
Neuro Oncol; 2023 Feb; 25(2):263-276. PubMed ID: 35609569
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of glioblastoma stem cells in the context of the immune microenvironment and geospatial organization.
Silver A; Feier D; Ghosh T; Rahman M; Huang J; Sarkisian MR; Deleyrolle LP
Front Oncol; 2022; 12():1022716. PubMed ID: 36338705
[TBL] [Abstract][Full Text] [Related]
16. Stem cell signature in glioblastoma: therapeutic development for a moving target.
Nakano I
J Neurosurg; 2015 Feb; 122(2):324-30. PubMed ID: 25397368
[TBL] [Abstract][Full Text] [Related]
17. DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development.
Binder H; Willscher E; Loeffler-Wirth H; Hopp L; Jones DTW; Pfister SM; Kreuz M; Gramatzki D; Fortenbacher E; Hentschel B; Tatagiba M; Herrlinger U; Vatter H; Matschke J; Westphal M; Krex D; Schackert G; Tonn JC; Schlegel U; Steiger HJ; Wick W; Weber RG; Weller M; Loeffler M
Acta Neuropathol Commun; 2019 Apr; 7(1):59. PubMed ID: 31023364
[TBL] [Abstract][Full Text] [Related]
18. Multiscale, multimodal analysis of tumor heterogeneity in IDH1 mutant vs wild-type diffuse gliomas.
Berens ME; Sood A; Barnholtz-Sloan JS; Graf JF; Cho S; Kim S; Kiefer J; Byron SA; Halperin RF; Nasser S; Adkins J; Cuyugan L; Devine K; Ostrom Q; Couce M; Wolansky L; McDonough E; Schyberg S; Dinn S; Sloan AE; Prados M; Phillips JJ; Nelson SJ; Liang WS; Al-Kofahi Y; Rusu M; Zavodszky MI; Ginty F
PLoS One; 2019; 14(12):e0219724. PubMed ID: 31881020
[TBL] [Abstract][Full Text] [Related]
19. IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.
Gorovets D; Kannan K; Shen R; Kastenhuber ER; Islamdoust N; Campos C; Pentsova E; Heguy A; Jhanwar SC; Mellinghoff IK; Chan TA; Huse JT
Clin Cancer Res; 2012 May; 18(9):2490-501. PubMed ID: 22415316
[TBL] [Abstract][Full Text] [Related]
20. Expression of CD40 Correlates Negatively with Overall and Progression-Free Survival of Low- and High-Grade Gliomas.
Werner JM; Kuhl S; Ulrich K; Krischek B; Stavrinou P; Goldbrunner R; Timmer M
World Neurosurg; 2019 Oct; 130():e17-e25. PubMed ID: 31125770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
